Skip to main content

A Randomized, Double-blind, Placebo Controlled 25-week Trial to Compare the Effect of Tiotropium Inhalation Capsuled (18 Mcg) Once Daily on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 8 Weeks of Pulmonary Rehabilitation.

  • NCT00274521
  • PHASE3
  • INTERVENTIONAL

Last updated: 2013-11-01

Purpose of  Trial

The study was designed to determine whether tiotropium inhalation capsules, compared to placebo, enhances the improvement in exercise tolerance seen in patients with chronic obstructive pulmonary disease (COPD) who participate in pulmonary rehabilitation. In addition, assessments of the effect of tiotropium on dyspnea and quality of life following pulmonary rehabilitation were taken.


This study is for people with

Pulmonary Disease, Chronic Obstructive


Interventions being studied

Tiotropium

Register to Save
ELIGIBILITY

Gender: ALL

Age: 40+

Healthy Volunteers: No

19 Locations
Birmingham

University of Alabama at Birmingham


Alabama, United States
Phoenix

Boehringer Ingelheim Investigational Site


Arizona, United States
Deer Park

Attention: John E. Hodgkin, M.D.


California, United States
Long Beach

Boehringer Ingelheim Investigational Site


California, United States
Los Angeles

UCLA School of Medicine


California, United States
San Diego

Boehringer Ingelheim Investigational Site


California, United States
Torrance

Harbor-UCLA Research and Education Institute


California, United States
Fort Collins

Boehringer Ingelheim Investigational Site


Colorado, United States
Wheat Ridge

Boehringer Ingelheim Investigational Site


Colorado, United States
Danbury

Boehringer Ingelheim Investigational Site


Connecticut, United States
Hartford

St. Francis Hospital and Medical Center


Connecticut, United States
Norwalk

Norwalk Hospital


Connecticut, United States
Elk Grove Village

Boehringer Ingelheim Investigational Site


Illinois, United States
North Worcester

UMass Memorial Medical Center


Massachusetts, United States
Detroit

Henry Ford Hospital


Michigan, United States
Omaha

University of Nebraska Medical Center


Nebraska, United States
Durhan

Duke University Medical Center


North Carolina, United States
Philadelphia

Temple University Hospital


Pennsylvania, United States
Everett

Boehringer Ingelheim Investigational Site


Washington, United States
Primary Contact(s)

Boehringer Ingelheim

Data obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Learn more at ClinicalTrials.gov

Back to Results New Search